Strip of 10 Units
Old MRP ₹207.8
MRP ₹194.81
₹142.21
₹19.48/Units
Use current location
Login to view saved addresses
100% genuine medicines
Safe & secure payments
15 days Easy returns
Prescription required for this medicine
Store Below 30o C
CompositionAjaDuo 25/5 mg Tablet is used to manage blood sugar levels in adults with type 2 diabetes mellitus. It helps improve glucose control and also reduces the risk of cardiovascular death and hospitalisation due to heart failure in high-risk patients. Take this medicine exactly as prescribed along with diet and exercise. Inform your doctor about existing medical conditions or medicines. Continue treatment regularly for sustained diabetes and heart protection.
Ajaduo 25mg/5mg Tablet is used to manage blood sugar levels in adults with type 2 diabetes mellitus. It also helps reduce the risk of cardiovascular death in diabetic patients with existing heart disease and lowers the risk of hospitalisation due to heart failure, supporting both glycaemic control and heart health.
Follow these instructions while taking AjaDuo 25/5 mg Tablet :
AjaDuo 25/5 mg Tablet is taken orally.
Ajaduo 25 mg/5 mg Tablet may cause side effects such as upper respiratory tract infections, nasopharyngitis (common cold), urinary tract infections, and increased frequency of urination. Maintain proper hydration and consult your doctor if symptoms persist.
Most side effects are temporary and generally harmless, which resolve on discontinuing the use of AjaDuo 25/5 mg Tablet. However, if you experience any serious side effects or worsening of any of the symptoms, please consult your doctor.
Upper respiratory tract infection: Keep hydrated and rest well. Warm liquids can also soothe your throat.
Increased urination: Ensure you stay hydrated by drinking plenty of water throughout the day.
AjaDuo 25/5 mg Tablet comprises two active ingredients:
Empagliflozin (25 mg): This ingredient is a sodium-glucose co-transporter 2 (SGLT2) inhibitor. It reduces glucose reabsorption from your kidneys, leading to increased glucose excretion through urine. This process helps lower plasma glucose levels, effectively managing your blood sugar levels.
Linagliptin (5 mg): As a dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin slows down the inactivation of incretin hormones. Incretins are a group of metabolic hormones that reduce blood sugar levels in a glucose-dependent manner. By keeping these hormones active for longer, linagliptin helps reduce both fasting and post-meal blood sugar concentrations.
If you are pregnant, caution is advised while taking AjaDuo 25/5 mg Tablet. It is not recommended during the second and third trimesters of pregnancy. Always consult your doctor before taking this medicine.
Breastfeeding mothers should avoid using AjaDuo 25/5 mg Tablet as there may be a risk to the developing baby. It's best to consult your doctor for advice.
The interaction of AjaDuo 25/5 mg Tablet with alcohol is unknown. Caution is advised. Always consult your doctor before consuming alcohol while taking this medicine.
AjaDuo 25/5 mg Tablet should be used cautiously if you have liver health issues. Always discuss your liver health status with your doctor before starting this medicine.
Caution is advised while taking AjaDuo 25/5 mg Tablet if you have kidney health issues. This medicine is contraindicated in severe renal impairment, end-stage renal disease, or dialysis. Your doctor will guide you based on your health status.
AjaDuo 25/5 mg Tablet does not interfere with your ability to drive or operate machinery. However, it's always safe to consult your doctor for advice.
Do not take this medicine if you have a history of serious hypersensitivity to empagliflozin, linagliptin, or any other ingredients in Ajaduo 25/5 mg Tablet.
AjaDuo 25/5 mg Tablet is not recommended for use in children as its safety and effectiveness have not been established in this age group.
Elderly patients can take AjaDuo 25/5 mg Tablet under medical supervision as they may be more susceptible to its side effects. It's important to ensure renal function is assessed, particularly in elderly patients, before starting this medicine.
Diuretics: Empagliflozin in AjaDuo 25/5 mg Tablet can interact with diuretics, like furosemide or hydrochlorothiazide, and can increase the risk of low blood pressure.
CYP3A4 inducers: Medicines such as rifampin can decrease the efficacy of linagliptin in AjaDuo 25/5 mg Tablet. You may need to consider alternative treatments.
High-fat meals: Consuming a high-fat meal before taking an AjaDuo 25/5 mg Tablet may increase the medication's absorption, potentially affecting its effectiveness.
Renal disease: If you have severe renal impairment, end-stage renal disease, or are on dialysis, AjaDuo 25/5 mg Tablet is not recommended as it can exacerbate your condition.
Pancreatitis: If you have a history of pancreatitis, use AjaDuo 25/5 mg Tablet cautiously. Linagliptin in AjaDuo has been linked to cases of acute pancreatitis.
Heart failure: Those with a prior history of heart failure or renal impairment should be monitored for signs and symptoms of heart failure while using AjaDuo 25/5 mg Tablet. In case heart failure develops during therapy, consider discontinuation.
The daily dose of AjaDuo 25/5 mg Tablet should be taken as directed by your doctor. The dosage depends on individual factors, such as the severity of your condition and your response to treatment. Always stick to the prescribed dosage and never exceed it without consulting your doctor. For further details regarding dosage, consult the package insert.
If you happen to take more AjaDuo 25/5 mg Tablet than recommended, you may experience symptoms like excessive thirst or increased urination. It is important to inform your doctor if these symptoms persist.
If you forget to take a dose of AjaDuo 25/5 mg Tablet, take it as soon as you remember. If you realise this is close to your next scheduled dose, skip the missed one and continue with your regular dosage schedule. Never double up on doses without consulting your doctor.
Store AjaDuo 25/5 mg Tablet at a temperature not exceeding 30°C.
Keep the medicine in a cool, dry place, away from direct sunlight.
Ensure this medicine is out of sight and reach of children.
Always check the expiry date before taking your dose.
As part of managing your type 2 diabetes, aim to maintain a balanced diet. This means consuming controlled portions of carbohydrates and including more high-fibre foods like whole grains, fruits, and vegetables in your meals.
Regular physical activity can help control your blood sugar levels. Try to engage in moderate exercise, such as brisk walking or cycling, for at least 30 minutes each day. Always consult your doctor before starting any new exercise regimen.
| Available Dosage Types | Tablet |
| Habit Forming | No |
| Ailment | 2 diabetes, Cardiovascular disease |
| Drug Category | SGLT2 inhibitor, DPP-4 inhibitor |
| Therapeutic Category | Antidiabetic |
AjaDuo 25/5 mg Tablet improves blood sugar control in adults with type 2 diabetes when diet and exercise alone are not enough.
You should take one AjaDuo 25/5 mg Tablet as prescribed by your doctor.
Yes, some common side effects include upper respiratory tract infection, nasopharyngitis, urinary tract infection and increased urination.
AjaDuo 25/5 mg Tablet is not recommended during the second and third trimesters of pregnancy. Always consult your doctor.
If you have severe renal impairment, end-stage renal disease or require dialysis, you should not take AjaDuo 25/5 mg Tablet.
If you experience a serious allergic reaction to this medicine, discontinue its use immediately and seek prompt medical attention.
Yes, but it may increase the risk of hypoglycaemia when used with insulin or insulin secretagogues. Always consult your doctor for advice.
Check out Editorial Policy
MedlinePlus. (2024, April 1). Empagliflozin. Retrieved from https://medlineplus.gov/druginfo/meds/a614043.html
MedlinePlus. (2024, April 1). Linagliptin. Retrieved from https://medlineplus.gov/druginfo/meds/a611036.html
U.S. Food & Drug Administration. (2022). Jardiance (empagliflozin) tablets, for oral use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/204629s034lbl.pdf
U.S. Food & Drug Administration. (2023). Tradjenta (linagliptin) tablets, for oral use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/201280s027lbl.pdf
We, at Truemeds make a diligent attempt to deliver accurate, expert- drafted and thoroughly reviewed medicine related information to our consumers. However, it should, by no means, be considered a substitute for prescription from a certified doctor or a trustworthy doctor-patient relationship. In fact we detest any form of self medication without expert advice. The sole purpose of the information on our portal is to educate our consumers, which helps improve the communication between a doctor and a patient. The information by no means is complete in its entirety and should not be used to diagnose or treat any medical condition. No amount of information can replace the experience and expertise of a doctor, therefore his/her advice always holds priority and should be followed appropriately.
50.1% CHEAPER
400 + users bought this instead
...View more
...View more
...View more
Company
About UsHealth ArticleHealth StoriesHealth LibraryDiseases & Health ConditionsAyurvedaUnderstanding Generic MedicinesAll MedicinesAll BrandsNeed HelpFAQSecuritySavings CalculatorSubscribe
Registered Office Address
Grievance Officer
Download Truemeds
Contact Us
Our customer representative team is available 7 days a week from 9 am - 9 pm.
v4.14.0
2026 - Truemeds | All rights reserved. Our content is for informational purposes only. See additional information.
Our Payment Partners
